Epitope for switching to T
The present invention relates to a novel epitope to convert T cell to type 17 helper T (T H 17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to T H 17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.
1. A method for converting a target T cell to a type 17 helper T (T H 17) cell, comprising:
(a) inducing expression of activation-inducible tumor necrosis factor receptor (AITR) in a target T cell using anti-CD-3/IL-2; and
(b) treating the target T cell using an antibody comprising
a heavy chain variable region comprising heavy chain complementarity-determining region 1 (CDR1) represented by SEQ ID NO: 6; heavy chain CDR2 represented by SEQ ID NO: 7; and a heavy chain CDR 3 represented by SEQ ID NO: 8; and
a light chain variable region comprising light chain CDR1 represented by SEQ ID NO: 10; light chain CDR2 represented by SEQ ID NO: 11; and light chain CDR3 represented by SEQ ID NO: 12,
thereby converting a target T cell to a type 17 helper T (T H 17) cell.
2. The method of claim 1 , wherein the target T cell is a type 1 helper T (T H 1) cell, a type 2 helper T (T H 2) cell, or a regulatory T (T reg ) cell.
3. The method of claim 1 , wherein the antibody comprises an amino acid sequence of a heavy chain variable region represented by SEQ ID NO: 5; and an amino acid sequence of a light chain variable region represented by SEQ ID NO: 9.
4. The method of claim 1 , wherein the type 17 helper T (T H 17) cell converted by the method increases a level of IL-17A secretion relative to that of the target T cell.
5. The method of claim 1 , wherein the target T cell is obtained by removal from a subject having an infectious disease.
6. The method of claim 5 , wherein the converted 17 helper T (T H 17) cell is administered to the subject having an infectious disease.
7. The method of claim 5 , wherein the infectious disease is selected from the group consisting of a viral infection, a fungal infection, a bacterial infection, a protozoan infection, and a parasitic infection.
8. The method of claim 1 , wherein the target T cell is obtained by removal from a healthy subject.
9. A method for treating an infectious disease, comprising:
(a) obtaining a target T cell from a subject having an infectious disease;
(b) inducing expression of activation-inducible tumor necrosis factor receptor (AITR) in the target T cell using anti-CD-3/IL-2;
(c) converting the target T cell to a type 17 helper T (T H 17) cell by using an antibody comprising
a heavy chain variable region comprising heavy chain complementarity-determining region 1 (CDR1) represented by SEQ ID NO: 6; heavy chain CDR2 represented by SEQ ID NO: 7; and a heavy chain CDR 3 represented by SEQ ID NO: 8; and
a light chain variable region comprising light chain CDR1 represented by SEQ ID NO: 10; light chain CDR2 represented by SEQ ID NO: 11; and light chain CDR3 represented by SEQ ID NO: 12; and
(d) administering the converted type 17 helper T (TH17) cell to the subject having an infectious disease,
thereby treating an infectious disease.
10. The treating method of claim 9 , wherein the target T cell is a type 1 helper T (T H 1) cell, a type 2 helper T (T H 2) cell, or a regulatory T (T reg ) cell.
11. The treating method of claim 9 , wherein the infectious disease is selected from the group consisting of a viral infection, a fungal infection, a bacterial infection, a protozoan infection, and a parasitic infection.
12. The method of claim 1 , wherein AITR expression is induced by stimulating the target T cell with anti-CD3/IL-2 for 2-5 days.
13. The method of claim 1 , wherein treating the target T cell comprises incubating with the antibody for 7 days.
14. The method of claim 13 , further comprising adding IL-2 to the antibody incubation every 2 days.
15. The method of claim 9 , wherein AITR expression is induced by stimulating the target T cell with anti-CD3/IL-2 for 2-5 days.
16. The method of claim 9 , wherein converting the target T cell to a type 17 helper T (T H 17) cell comprises incubating the target T cell with the antibody of step (c) for 7 days.
17. The method of claim 9 , further comprising adding IL-2 to the antibody incubation of step (c) every 2 days.